TNO is the coordinator of CarTarDis, will manage the entire project (WP5) and will be responsible for exploitation and dissemination (WP6). TNO will contribute its proprietary humanized mouse disease models and cell models and will be participant in WP2 (Target validation- in vitro and in vivo models) and in WP4 (Drug target prioritization).
The Netherlands Organization for Applied Scientific Research (TNO) is an independent research and technology organization with about 3500 employees (~80% academics) clustered in about 70 research groups. Its mission is to apply knowledge to improve the competitiveness of companies and to assist governmental bodies and public organizations to improve well-being of the society. TNO has a longstanding tradition in the area of metabolic disease and has gained an internationally recognized expert position in the field of cardio-metabolic disease and inflammatory processes involved therein. TNO has developed proprietary humanized mouse disease models for cardiovascular and metabolic diseases (APOE*3-Leiden(.CETP) transgenic mice) and their complications in which state-of-the-art read-out technologies are applied. In the past 6 years, TNO has performed 290 preclinical studies of atherosclerosis and diabetes, most of which were conducted in translational humanized animal models. The preclinical models are being combined with other robust platforms at TNO (including pharmacokinetics, molecular profiling, system biology-based bioinformatics, statistics and modeling) to understand mechanism-of-action of therapies in relation to pharmacological outcomes. Knowledge on efficacy and safety of interventions are being translated from pre-clinic to clinic through dedicated experimental medicine studies in man.